Effect of increasing dietary folate on red-cell folate: implications for prevention of neural tube defects

doi:10.1016/S0140-6736(96)91205-2

The Lancet

Volume 347, Issue 9002, 9 March 1996, Pages 657-659

https://doi.org/10.1016/S0140-6736(96)91205-2 Get rights and content

Abstract

Summary

Background Recommendations by the UK Department of Health suggest that protection from neural tube defects (NTD) can be achieved through intakes of an extra 400 μg daily of folate/folic acid as natural food, foods fortified with folic acid, or supplements. The assumption is that all three routes of intervention would have equal effects on folate status.

Methods We assessed the effectiveness of these suggested routes of intervention in optimising folate status. 62 women were recruited from the University staff and students to take part in a 3-month intervention study. Participants were randomly assigned to one of the following five groups: folic acid supplement (400 μg/day; I); folic-acid-fortified foods (an additional 400 μg/day; II); dietary folate (an additional 400 μg/day; III); dietary advice (IV), and control (V). Responses to intervention were assessed as changes in red-cell folate between preintervention and postintervention values.

Findings 41 women completed the intervention study. Red-cell folate concentrations increased significantly over the 3 months in the groups taking folic acid supplements (group I) or food fortified with folic acid (group II) only (p<0·01 for both groups). By contrast, although aggressive intervention with dietary folate (group III) or dietary advice (group IV) significantly increased intake of food folate (p<0·001 and p<0·05, respectively), there was no significant change in folate status.

Interpretation We have shown that compared with supplements and fortified food, consumption of extra folate as natural food folate is relatively ineffective at increasing folate status. We believe that advice to women to consume folate-rich foods as a means to optimise folate status is misleading.

References (12)

Mrc Vitamin Study Research Group
Prevention of neural tube defects: results of the MRC Vitamin Study
Lancet
(1991)
Department of Health. Folic acid and the prevention of neural tube defects. Report from an expert advisory group....
Centers for Disease Control
Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects
MMWR Morbid Mortal Wkly Rep
(1992)
National Health and Medical Research Council
Revised statement on the relationship between dietary folic acid and neural tube defects such as spina bifida. 115th session
(1993)
Jf Gregory
The bioavailabiity of folate

There are more references available in the full text version of this article.

Cited by (296)

Low-dose daily folic acid (400 μg) supplementation does not affect regulation of folate transporters found present throughout the terminal ileum and colon of humans: a randomized clinical trial
2024, American Journal of Clinical Nutrition
Folic acid supplementation during the periconceptional period reduces the risk of neural tube defects in infants, but concern over chronic folic acid exposure remains. An improved understanding of folate absorption may clarify potential risks. Folate transporters have been characterized in the small intestine, but less so in the colon of healthy, free-living humans. The impact of folic acid fortification or supplementation on regulation of these transporters along the intestinal tract is unknown.
The objective was to characterize expression of folate transporters/receptor (FT/R) and folate hydrolase, glutamate carboxypeptidase II (GCPII), from the terminal ileum and throughout the colon of adults and assess the impact of supplemental folic acid.
In this 16-wk open-labeled randomized clinical trial, adults consumed a low folic acid-containing diet, a folate-free multivitamin, and either a 400 μg folic acid supplement or no folic acid supplement. Dietary intakes and blood were assessed at baseline, 8 wk, and 16 wk (time of colonoscopy). Messenger RNA (mRNA) expression and protein expression of FT/R and GCPII were assessed in the terminal ileum, cecum, and ascending and descending colon.
Among 24 randomly assigned subjects, no differences in dietary folate intake or blood folate were observed at baseline. Mean ± SD red blood cell folate at 16 wk was 1765 ± 426 and 911 ± 242 nmol/L in the 400 and 0 μg folic acid group, respectively (P < 0.0001). Reduced folate carrier, proton-coupled folate transporter, and folate-receptor alpha expression were detected in the terminal ileum and colon, as were efflux transporters of breast cancer resistance protein and multidrug resistance protein-3. Other than a higher mRNA expression of FR-alpha and GCPII in the 400 μg supplement group in the ascending colon, no treatment differences were observed (P < 0.02).
Folate transporters are present throughout the terminal ileum and colon; there is little evidence that a low dose of folic acid supplementation affects colonic absorption.
This trial was registered at clinicaltrials.gov as NCT03421483.
Pregnancy: Prevention of neural tube defects
2023, Encyclopedia of Human Nutrition: Volume 1-4, Fourth Edition
Neural tube defects (NTDs) are major congenital malformations of the central nervous system occurring when the neural tube fails to close properly in the developing fetus, resulting in death or lifelong disability. The finding that folic acid can prevent NTDs ranks as one of the most important discoveries in birth defects research, and indeed in human nutrition. This article will review the nutrition and genetic factors in the etiology of NTDs and summarize the mechanisms underlying the link between folate and NTD. Policy for preventing NTD will be discussed, including mandatory food fortification programs aimed at reducing the population prevalence of NTDs.
Associations between folic acid supplement use and folate status biomarkers in the first and third trimesters of pregnancy in the Maternal–Infant Research on Environmental Chemicals (MIREC) Pregnancy Cohort Study
2022, American Journal of Clinical Nutrition
Achieving optimal folate status during early gestation reduces the risk of neural tube defects (NTDs). While inadequate folate intake remains a concern, it is becoming increasingly common for individuals to consume higher than recommended doses of folic acid (FA) with minimal additional benefit.
Here, we sought to investigate the determinants, including FA supplement dose and use, of plasma total and individual folate vitamer concentrations in the first and third trimesters of pregnancy.
Using data from the Maternal–Infant Research on Environmental Chemicals (MIREC) Study, a cohort exposed to mandatory FA fortification, we measured plasma total folate and individual folate vitamer [5-methyltetrahydrofolate (5-methylTHF), unmetabolized FA (UMFA), and non-methyl folates (sum of THF, 5-formylTHF, 5,10-methenyl-THF)] concentrations in the first and third trimesters (n = 1,893). Using linear mixed models, we estimated associations between plasma folate concentrations, total daily supplemental FA intake, plasma vitamin B-12 concentrations, and multiple demographic, maternal, and reproductive factors.
Almost 95% of MIREC study participants met or exceeded the recommended daily supplemental FA intake from supplements (≥400 μg/d), with approximately 25% consuming more than the Tolerable Upper Intake Level (>1000 μg/d). Over 99% of MIREC participants had a plasma total folate status indicative of maximal NTD risk reduction (25.5 nmol/L) regardless of FA supplement dose. UMFA was detected in almost all participants, with higher concentrations associated with higher FA doses. Determinants of adequate FA supplement intake and folate status associated with reduced NTD risk included indicators of higher socioeconomic position, higher maternal age, nulliparity, and lower prepregnancy BMI.
In the context of mandatory FA fortification, our data indicate that higher-than-recommended FA doses are unwarranted, with the exception of individuals at higher risk for NTDs. Ideally, prenatal supplements would contain 400 rather than 1000 µg FA, thereby enabling the consumption of optimal and safe FA doses.
The bioaccessibility of water-soluble vitamins: A review
2021, Trends in Food Science and Technology
Water-soluble vitamins are indispensable organic molecules for growth, development, and body function. Epidemiological evidence often supports the link between sufficient dietary intake of water-soluble vitamins and maintaining overall health. Knowing the bioaccessibility and bioavailability of water-soluble vitamins are important in terms of their usability in metabolism. There are many studies about the bioaccessibility and bioavailability of food components, but studies about vitamins are limited.
The purpose of this review was to evaluate the bioaccessibility of water-soluble vitamins and identify the factors that may negatively affect the bioaccessibility. In this review, we focused on summarizing the bioaccessibility of water-soluble vitamins. The influence of dietary fiber and its properties, temperature, pH, grinding, inhibitors, antioxidants, polypeptides, polysaccharides, and vitamin-binding proteins on the bioaccessibility of vitamins was evaluated. However, the bioavailability values for some water-soluble vitamins were also presented, but there is a limited study about the bioavailability of water-soluble vitamins.
Bioaccessibility may decrease significantly in vitamin C, folate, vitamin B₁, and the PL and PM forms of vitamin B₆, which are more sensitive to temperature and acidity. Generally, decreases in pH-sensitive vitamins may occur in the small intestine, where pH value is higher than the gastric phase. Also, the presence of some metal ions, bonding with polypeptides and polysaccharides, digestive enzyme inhibitors, dietary fiber, and binding proteins may negatively affect bioaccessibility. The numbers of studies conducted in this field are limited. In conclusion, more studies are suggested to obtain more accurate information about the current dietary nutrient intake.
Global Status of Folic Acid Fortification—Progress and Gaps
2018, Food Fortification in a Globalized World
This chapter reviews the evidence basis for prevention of folic acid-sensitive neural tube defects (NTDs) through public health interventions in women of reproductive age (WRA), the proven vehicles for delivery of folic acid, what is needed to effectively scale these, and a snapshot of potential innovations which require future research. The primary focus is on the global situation affecting large-scale food fortification (LSFF) with folic acid, in particular the fortification of wheat flour and maize meal. The overarching conclusion is that folic acid fortification is an evidenced-based intervention that reduces the prevalence of NTDs, and that LSFF with folic acid is underutilized. Thus, food fortification with folic acid should be a component of most national public health strategies, in particular where: (1) folate status is insufficient; and (2) there is a fortifiable food vehicle consumed regularly by WRA that is processed by centralized industry. The evidence shows that there is still much work needed to (1) build the enabling environment and expand programs where there is currently no legislation; (2) improve the low quality of delivery of existing programs; and (3) measure and sustain programs by generating new coverage data and demonstrating evidence of impact in low- and middle-income countries.
Authorised EU health claim for supplementary folic acid
2018, Foods, Nutrients and Food Ingredients with Authorised EU Health Claims
A reduction of disease risk health claim that ‘Supplemental folic acid intake increases maternal folate status. Low maternal folate status is a risk factor in the development of neural tube defects in the developing foetus’ was authorised in the European Union in 2014 for use on 400 μg/day folic acid supplements. The target group is women of childbearing age. The conditions of use specify that the supplement should be consumed for at least 1 month before and up to 3 months after conception. The claim is well substantiated by data from intervention trials and supported by observational data. Though the need to take a daily 400-μg folic acid supplement to protect against neural tube defects is a global WHO recommendation and many EU Member States give this advice, uptake of supplementation by the target group is low. As some studies have shown that low compliance is associated with poor knowledge of the message, the health claim is an important additional means of communication to raise awareness of this important public health recommendation.

View all citing articles on Scopus

View full text

Early reportsEffect of increasing dietary folate on red-cell folate: implications for prevention of neural tube defects

Abstract

Prevention of neural tube defects: results of the MRC Vitamin Study

Lancet

Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects

MMWR Morbid Mortal Wkly Rep

Revised statement on the relationship between dietary folic acid and neural tube defects such as spina bifida. 115th session

The bioavailabiity of folate

Early reports
Effect of increasing dietary folate on red-cell folate: implications for prevention of neural tube defects